{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:47:25Z","timestamp":1793033245082,"version":"4.5.0"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2023,4,5]],"date-time":"2023-04-05T00:00:00Z","timestamp":1680652800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,6]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>To describe the labeling, packaging practices, and characteristics of compounded 0.01% ophthalmic atropine.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A convenience sample of parents of children who had previously been prescribed low-concentration atropine for myopia management were randomized to obtain 0.01% atropine ophthalmic solution from one of nine compounding pharmacies. The products were analyzed for various important quality attributes. The main outcomes were labeling practices, concentration of atropine and degradant product tropic acid, pH, osmolarity, viscosity, and excipients in 0.01% atropine samples obtained from nine US compounding pharmacies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Twenty-four samples from nine pharmacies were analyzed. The median bottle size was 10 mL (range 3.5\u201315 mL), and eight of nine pharmacies used clear plastic bottles. Storage recommendations varied and were evenly split between refrigeration (33%), room temperature (33%), and cool, dark, dry location (33%). Beyond use dates ranged from 7 to 175 days (median, 91 days). Median pH of samples was 7.1 (range, 5.5\u20137.8). Median measured concentration relative to the prescribed concentration was 93.3% (70.4%\u2013104.1%). One quarter of samples were under the 90% minimum target concentration of 0.01%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>An inconsistent and wide variety of formulation and labeling practices exist for compounding 0.01% atropine prescribed to slow pediatric myopia progression.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/icl.0000000000000990","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T10:01:27Z","timestamp":1680775287000},"page":"219-223","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":21,"title":["Compounded 0.01% Atropine\u2014What's in the Bottle?"],"prefix":"10.1097","volume":"49","author":[{"given":"Kathryn","family":"Richdale","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelsea V.","family":"Skidmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin S.","family":"Tomiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A.","family":"Bullimore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,4,5]]},"reference":[{"key":"R1-20250601","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.ophtha.2017.05.032","article-title":"Atropine for the prevention of myopia progression in children: A report by the American Academy of Ophthalmology","volume":"124","author":"Pineles","year":"2017","journal-title":"Ophthalmology"},{"key":"R2-20250601","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40268-013-0005-9","article-title":"Potential risks of pharmacy compounding","volume":"13","author":"Gudeman","year":"2013","journal-title":"Drugs R D"},{"key":"R3-20250601","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s13181-020-00814-3","article-title":"Pharmaceutical compounding: A history, regulatory overview, and systematic review of compounding errors","volume":"17","author":"Watson","year":"2021","journal-title":"J Med Toxicol"},{"key":"R4-20250601","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/jcm10040588","article-title":"Corneal penetration of low-dose atropine eye drops","volume":"10","author":"Austermann","year":"2021","journal-title":"J Clin Med"},{"key":"R5-20250601","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/ICL.0000000000000932","article-title":"Compounding of low-concentration atropine for myopia control","volume":"48","author":"Richdale","year":"2022","journal-title":"Eye Contact Lens"},{"key":"R6-20250601","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.3891\/acta.chem.scand.22-3085","article-title":"The kinetics of atropine and apoatropine in aqueous solutions","volume":"22","author":"Lund","year":"1968","journal-title":"Acta Chem Scand"},{"key":"R7-20250601","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.ophtha.2006.05.062","article-title":"Atropine for the treatment of childhood myopia","volume":"113","author":"Chua","year":"2006","journal-title":"Ophthalmology"},{"key":"R8-20250601","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study: A randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"R9-20250601","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41433-020-1122-7","article-title":"A 3-year follow-up study of atropine treatment for progressive myopia in Europeans","volume":"34","author":"Polling","year":"2020","journal-title":"Eye (Lond)"},{"key":"R10-20250601","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40780-019-0154-2","article-title":"Physical, chemical, and microbiological stability study of diluted atropine eye drops","volume":"5","author":"Saito","year":"2019","journal-title":"J Pharm Health Care Sci"},{"key":"R11-20250601","doi-asserted-by":"crossref","first-page":"781","DOI":"10.3390\/pharmaceutics12080781","article-title":"Stability of ophthalmic atropine solutions for child myopia control","volume":"12","author":"Berton","year":"2020","journal-title":"Pharmaceutics"},{"key":"R12-20250601","doi-asserted-by":"crossref","first-page":"91","DOI":"10.33192\/Smj.2022.12","article-title":"Stability and sterility of extemporaneously prepared 0.01% atropine ophthalmic solution in artificial tears and balanced salt solution","volume":"74","author":"Sri-in","year":"2022","journal-title":"Siriraj Med J"},{"key":"R13-20250601","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamaophthalmol.2014.3591","article-title":"Evaluation of compounded bevacizumab prepared for intravitreal injection","volume":"133","author":"Yannuzzi","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R14-20250601","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ajo.2011.11.023","article-title":"Avastin doesn't blind people, people blind people","volume":"153","author":"Gonzalez","year":"2012","journal-title":"Am J Ophthalmol"},{"key":"R15-20250601","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1097\/ICO.0000000000000368","article-title":"Osmolarity of prevalent eye drops, side effects, and therapeutic approaches","volume":"34","author":"Dutescu","year":"2015","journal-title":"Cornea"},{"key":"R16-20250601","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1136\/bjo.68.8.549","article-title":"Dynamics of ocular surface pH","volume":"68","author":"Coles","year":"1984","journal-title":"Br J Ophthalmol"},{"key":"R17-20250601","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/ICL.0000000000000498","article-title":"A drug to prevent pediatric myopia-what would it take?","volume":"44","author":"Novack","year":"2018","journal-title":"Eye Contact Lens: Sci Clin Pract"},{"key":"R18-20250601","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.ophtha.2021.10.002","article-title":"Three-Year clinical trial of low-concentration atropine for myopia progression (LAMP) study: Continued versus washout","volume":"129","author":"Yam","year":"2022","journal-title":"Ophthalmology"},{"key":"R19-20250601","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s00417-018-4078-6","article-title":"Current trends among pediatric ophthalmologists to decrease myopia progression-an international perspective","volume":"256","author":"Zloto","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R20-20250601","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1136\/bjophthalmol-2019-314752","article-title":"Practice patterns to decrease myopia progression differ among paediatric ophthalmologists around the world","volume":"104","author":"Leshno","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R21-20250601","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMp1712905","article-title":"Toward better-quality compounded drugs\u2014an update from the FDA","volume":"377","author":"Woodcock","year":"2017","journal-title":"N Engl J Med"},{"key":"R22-20250601","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jtos.2021.09.004","article-title":"Compounded medications for ocular surface disease","volume":"22","author":"Lee","year":"2021","journal-title":"Ocul Surf"},{"key":"R26-20250601","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.jtos.2015.01.001","article-title":"Can I use those eyedrops after the expiration date?","volume":"13","author":"Novack","year":"2015","journal-title":"Ocul Surf"},{"key":"R30-20250601","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.preteyeres.2010.03.001","article-title":"Preservatives in eyedrops: The good, the bad and the ugly","volume":"29","author":"Baudouin","year":"2010","journal-title":"Prog Retin Eye Res"},{"key":"R33-20250601","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0014-4835(80)90114-1","article-title":"Increased corneal permeability induced by the dual effects of transient tear film acidification and exposure to benzalkonium chloride","volume":"30","author":"Keller","year":"1980","journal-title":"Exp Eye Res"},{"key":"R34-20250601","doi-asserted-by":"crossref","first-page":"e231","DOI":"10.2146\/ajhp161068","article-title":"Stability of extemporaneously prepared ophthalmic solutions for mydriasis","volume":"75","author":"Camp","year":"2018","journal-title":"Am J Health-System Pharm"},{"key":"R36-20250601","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.4155\/tde.14.75","article-title":"Advances in ophthalmic drug delivery","volume":"5","author":"Morrison","year":"2014","journal-title":"Ther Deliv"},{"key":"R37-20250601","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.3390\/polym10111221","article-title":"Strategies for Improving Ocular Drug Bioavailability and Corneal Wound Healing with Chitosan-Based Delivery Systems","volume":"10","author":"Irimia","year":"2018","journal-title":"Polymers (Basel)"},{"key":"R38-20250601","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1001\/jamaophthalmol.2017.6638","article-title":"Low-dose atropine for myopia control: Considering all the data","volume":"136","author":"Bullimore","year":"2018","journal-title":"JAMA Ophthalmol"}],"container-title":["Eye &amp; Contact Lens: Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ICL.0000000000000990","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T13:00:13Z","timestamp":1748782813000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/ICL.0000000000000990"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,5]]},"references-count":29,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/icl.0000000000000990","relation":{},"ISSN":["1542-2321"],"issn-type":[{"value":"1542-2321","type":"print"}],"subject":[],"published":{"date-parts":[[2023,4,5]]},"assertion":[{"value":"2023-03-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}